<DOC>
	<DOCNO>NCT00097617</DOCNO>
	<brief_summary>This study multicenter , open-label , observational , postmarketing surveillance study collect information use Genentech growth hormone ( GH ) preparation treat child CRI United States .</brief_summary>
	<brief_title>A Study Children With Growth Failure Due Chronic Renal Insufficiency ( CRI ) End Stage Renal Disease ( ESRD )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Failure Thrive</mesh_term>
	<criteria>Children diagnose CRI ESRD treat Genentech GH preparation 1 January 2001 CRI document use Schwartz formula indicate calculated creatinine clearance ( CrCl ) &lt; =75 mL/min/1.73 m^2 Ability keep follow appointment throughout study Subjects receive nonGenentech GH preparation Subjects close epiphysis Subjects active neoplasia Current participation another GH clinical study Current participation core study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>